Last July 14th, the ​​innovation and business development area of the Bellvitge Biomedical Research Institute (IDIBELL) participated in a new edition of ACCIÓ Investment Forum (Generalitat de Catalunya) through the presentation of Tractivus, one IDIBELL-IQS spin-off. This event, which reaches its 21st edition this year, is one of the main meeting points between entrepreneurs and investors in Catalonia.
Tractivus was one of 21 companies chosen to participate in the Investment Forum Award competition, which is awarded to the project with the greatest potential for innovation. Joan Gilabert, CEO of Tractivus, presented in a one-minute-long elevator pitch their design project of 3D-printed custom and antibacterial medical devices under the watchful eye of the audience, who chose him as 3rd runner-up in the field of health sciences. Finally, the Catalan company Nektria became the winner of the contest.
At the same time, the Forum also hosted 400 networking meetings between entrepreneurs, private investors and representatives of venture capital funds; IDIBELL had an active participation, introducing the projects that make up its portfolio of proposals for innovation and technology transfer, and seeking funding based on their business potential. In addition, this year the forum welcomed Mr Alon Lifshitz, Managing Director of Blumberg Capital, who was responsible for the inaugural conference, and companies and investors from Israel, the guest country of this edition.
The ACCIÓ Investment Forum also presented the Enterprise Catalog 2016, which includes the top 50 business projects from the 100 proposals received.